We will discuss how these adaptations depend both on the drug and the origin of the tumor and how they contribute to drug resistance, focussing on widely-used chemotherapeutics, including proteasome inhibitors (multiple myeloma), EGFR inhibitors (breast cancer), cisplatin (lung cancer/ovarian cancer) and BRAF inhibitors (melanoma). Here, BRAF is linked to plasma cell myeloma.